Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Submits Dapoxetine NDA For Premature Ejaculation

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.

You may also be interested in...



Dapoxetine Early 2006 Launch Expectations Premature, J&J Says

Johnson & Johnson does not expect FDA approval of its premature ejaculation therapy dapoxetine in time for an early 2006 launch

Dapoxetine Early 2006 Launch Expectations Premature, J&J Says

Johnson & Johnson does not expect FDA approval of its premature ejaculation therapy dapoxetine in time for an early 2006 launch

Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says

A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel